Tunicamycin-DataSheet-生命科學(xué)試劑-MedChemExpress

Hotline:400-820-3792Inhibitors?ScreeningLibraries?Proteinswww.MedChemETunicamycinCat.No.:HY-A0098CASNo.:11089-65-9分?式:C??H??N?O??作?靶點(diǎn):Bacterial;Fungal;InfluenzaVirus;Antibiotic作?通路:Anti-infection儲(chǔ)存?式:Powder-20°C3yearsInsolvent-80°C6months-20°C1month溶解性數(shù)據(jù)體外實(shí)驗(yàn)DMSO:40mg/mL(Needultrasonic)H2O:<0.1mg/mL(insoluble)請根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲(chǔ)備液；?旦配成溶液，請分裝保存，避免反復(fù)凍融造成的產(chǎn)品失效。儲(chǔ)備液的保存?式和期限：-80°C,6months;-20°C,1month。-80°C儲(chǔ)存時(shí)，請?jiān)?個(gè)?內(nèi)使?，-20°C儲(chǔ)存時(shí)，請?jiān)?個(gè)?內(nèi)使?。體內(nèi)實(shí)驗(yàn)請根據(jù)您的實(shí)驗(yàn)動(dòng)物和給藥?式選擇適當(dāng)?shù)娜芙?案。以下溶解?案都請先按照InVitro?式配制澄的儲(chǔ)備液，再依次添加助溶劑：(為保證實(shí)驗(yàn)結(jié)果的可靠性，澄的儲(chǔ)備液可以根據(jù)儲(chǔ)存條件，適當(dāng)保存；體內(nèi)實(shí)驗(yàn)的?作液，建議您現(xiàn)?現(xiàn)配，當(dāng)天使?；以下溶劑前顯?的百分?指該溶劑在您配制終溶液中的體積占?；如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過加熱和/或超聲的?式助溶)1.請依序添加每種溶劑：10%DMSO>>40%PEG300>>5%Tween-80>>45%salineSolubility:≥2mg/mL(InfinitymM);Clearsolution2.請依序添加每種溶劑：10%DMSO>>90%(20%SBE-β-CDinsaline)Solubility:≥2mg/mL(InfinitymM);Clearsolution3.請依序添加每種溶劑：10%DMSO>>90%cornoilSolubility:≥2mg/mL(InfinitymM);ClearsolutionBIOLOGICALACTIVITY?物活性Tunicamycin?種同核苷抗?素的混合物,可抑制N-糖化并阻斷GlcNAc磷酸轉(zhuǎn)移酶(GPT)。Tunicamycin引起細(xì)胞內(nèi)質(zhì)?(ER)中未折疊蛋?的積累并誘導(dǎo)ER應(yīng)激，并導(dǎo)致DNA合成受阻和G1期細(xì)胞周1/2MasterofBioactiveMolecules—您?邊的抑制劑?師www.MedChemE期停滯。Tunicamycin可抑制?蘭?陽性細(xì)，酵母，真和病毒，并具有抗癌活性。Tunicamycin增加宮頸癌細(xì)胞中外泌體的釋放。體外研究Tunicamycin(2μg/mL;24hours;CD44+/CD24-andoriginalMCF7cells)treatmentincreasesthesplicedXBP-1,ATF6nucleartranslocationlevelandCHOPproteinexpressioninCD44+/CD24-andoriginalMCF7cells[1].Tunicamycin-inducedERstresssuppressesCD44+/CD24-phenotypecellsubpopulationandinvitroinvasionandacceleratestumorosphoreformation.UndereffectofTunicamycin,theresultsshowthatinhibitedinvasion,increasedcelldeath,suppressedproliferationandreducedmigrationintheCD44+/CD24-andCD44+/CD24-richMCF7cellculture[1].WesternBlotAnalysisCellLine:CD44+/CD24-andoriginalMCF7cells[1]Concentration:2μg/mLIncubationTime:24hoursResult:IncreasedlevelofsplicedXBP-1,ATF6nucleartranslocationandCHOPproteinexpressionaredetectedinCD44+/CD24-andoriginalMCF7cells.體內(nèi)研究Tunicamycin(0.1mg/kgor0.5mg/kg)treatmentdramaticallysuppressestumorgrowthintheCD133+/-MHCC97Lcellsxenograftmodel(BALB/c(nu/nu)mice)[2].戶使?本產(chǎn)品發(fā)表的科研?獻(xiàn)?Nature.2020Mar;579(7799):433-437.?NatCommun.2022Apr6;13(1):1853.?Hepatology.2022Oct11.?EMBOMolMed.2022Jan11;14(1):e14502.?Autophagy.2021Jun;17(6):1426-1447.Seemorecustomervalidationsonwww.MedChemEREFERENCES[1].HsuJL,etal.Tunicamycininducesresistancetocamptothecinandetoposideinhumanhepatocellularcarcinomacells:roleofcell-cyclearrestandGRP78.NaunynSchmiedebergsArchPharmacol.2009Nov;380(5):373-82.[2].HanC,etal.Endoplasmicreticulumstressinhibitscellcycleprogressionviainductionofp27inmelanomacells.CellSignal.2013Jan;25(1):144-9.[3].HouH,etal.DPAGT1/Akt/ABCG2pathwayinmouseXenograftmodelsofhumanhepatocellularcarcinoma.MolCancerTher.2013Dec;12(12):2874-84.[4].KathleenMMcAndrews,etal.Mechanismsassociatedwithbiogenesisofexosomesincancer.MolCancer.2019Mar30;18(1):52.McePdfHeight2/2MasterofBioactiveMolecules—您?邊的抑制劑?師www.MedChemECaution:Producthasnotbeenfullyva